| Expression of ApoA5 and its function in the right ventricular failing and remodeling secondary to pulmonary hypertension. | Expression of ApoA5 and its function in the right ventricular failing and remodeling secondary to pulmonary hypertension.
Chen J, Luo J, Yang X, Ouyang M, Zhu T, Li Y, Luo P, Chen Y, Li Z, Li J. | 09/11/2021 |
| Our data support the hypothesis that apoA5 promotes hepatic TG storage and therefore contributes to the pathogenesis of non-alcoholic fatty liver disease | Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.
Feng Q, Baker SS, Liu W, Arbizu RA, Aljomah G, Khatib M, Nugent CA, Baker RD, Forte TM, Hu Y, Zhu L., Free PMC Article | 04/23/2016 |
| Demonstrate that apoA-V is secreted into bile, introducing a potential route of delivery of hepatic apoA-V to the gut lumen. | Apolipoprotein A-V is present in bile and its secretion increases with lipid absorption in Sprague-Dawley rats.
Zhang LS, Sato H, Yang Q, Ryan RO, Wang DQ, Howles PN, Tso P., Free PMC Article | 04/2/2016 |
| Upregulation of apoA5 expression contributes to the triglyceridelowering effect of statins via the PPARalpha signaling pathway. | [Statin reduced triglyceride level via activating peroxisome proliferator activated receptor α and upregulating apolipoprotein A5 in hypertriglyceridemic rats].
HUANG XS, ZHAO SP, BAI L, ZHANG Q, HU M, ZHAO W. | 10/22/2011 |
| The increase in apolipoprotein A mRNA induced by rosiglitazone is not directly mediated by peroxisome proliferator-activated receptor gamma.[apolipoprotein av] | Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
Dorfmeister B, Brandlhofer S, Schaap FG, Hermann M, Fürnsinn C, Hagerty BP, Stangl H, Patsch W, Strobl W. | 07/28/2011 |
| apoA-V inefficiently traffics within the secretory pathway, that its intracellular itinerary can be regulated by changes in cellular TG accumulation, and that apoA-V synthesis can modulate VLDL TG mobilization and secretion. | Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion.
Blade AM, Fabritius MA, Hou L, Weinberg RB, Shelness GS., Free PMC Article | 05/7/2011 |
| decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity | Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity.
Huang XS, Zhao SP, Hu M, Bai L, Zhang Q, Zhao W. | 12/11/2010 |
| ApoA-V ability to enhance insulin secretion in beta-cells and provide evidence of an internalization pathway involving the midkine as partner. | Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine.
Helleboid-Chapman A, Nowak M, Helleboid S, Moitrot E, Rommens C, Dehondt H, Héliot L, Drobecq H, Fruchart-Najib J, Fruchart JC. | 02/22/2010 |
| data suggest that the C terminus of apoA-V is essential for lipid droplet association in transfected hepatoma cells and lipoprotein association in conditioned medium while the signal peptide is required for extracellular trafficking of this protein. | Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment.
Shu X, Ryan RO, Forte TM., Free PMC Article | 01/21/2010 |
| The absence of significant changes in Apoa5 gene expression during chronic fructose-induced triglyceride elevation excludes its major role in mechanisms compensating severe hypertriglyceridemia | Apolipoprotein A5 and hypertriglyceridemia in Prague hypertriglyceridemic rats.
Kadlecová M, Hojná S, Bohuslavová R, Hubácek JA, Zicha J, Kunes J. | 01/21/2010 |
| the hypotriglyceridemic gene APOA5 is regulated by thyroid hormone | Thyroid hormone regulates the hypotriglyceridemic gene APOA5.
Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodríguez JC. | 01/21/2010 |